Fred D. Lublin
#57,635
Most Influential Person Now
American medical academic
Fred D. Lublin's AcademicInfluence.com Rankings
Fred D. Lublinphilosophy Degrees
Philosophy
#5486
World Rank
#8303
Historical Rank
#1426
USA Rank
Logic
#3127
World Rank
#4241
Historical Rank
#669
USA Rank
Download Badge
Philosophy
Fred D. Lublin's Degrees
- Doctorate Medicine Albert Einstein College of Medicine
Why Is Fred D. Lublin Influential?
(Suggest an Edit or Addition)According to Wikipedia, Fred D. Lublin is an American neurologist and an authority on the treatment of multiple sclerosis. Along with colleagues at the National Multiple Sclerosis Society, his work redefined the clinical course definitions of MS.
Fred D. Lublin's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria (2011) (8941)
- Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis (2001) (6788)
- Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” (2005) (5003)
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (2017) (3544)
- A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. (2006) (2970)
- Defining the clinical course of multiple sclerosis (1996) (2797)
- Defining the clinical course of multiple sclerosis (2014) (2372)
- Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. (2006) (1274)
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis (2017) (1170)
- Development of a multiple sclerosis functional composite as a clinical trial outcome measure. (1999) (1137)
- Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis (2017) (1107)
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial (2014) (647)
- Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines (2002) (641)
- Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis (1996) (471)
- Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study (2009) (435)
- Effect of relapses on development of residual deficit in multiple sclerosis (2003) (413)
- Recommendations from the national multiple sclerosis society clinical outcomes assessment task force (1997) (359)
- Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial (2016) (331)
- MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS (2007) (317)
- Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial (2019) (311)
- The Goldman Consensus statement on depression in multiple sclerosis (2005) (309)
- The incidence and significance of anti-natalizumab antibodies (2007) (260)
- Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters. (1995) (246)
- New Multiple Sclerosis Phenotypic Classification (2014) (234)
- Neuropsychological and structural brain lesions in multiple sclerosis (1992) (221)
- Health‐related quality of life in multiple sclerosis: effects of natalizumab (2007) (190)
- Management of patients receiving interferon beta-1b for multiple sclerosis (1996) (178)
- Clinical outcomes assessment in multiple sclerosis (1996) (172)
- Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines (2002) (171)
- Randomized study combining interferon and glatiramer acetate in multiple sclerosis (2013) (170)
- Clinical Course of Multiple Sclerosis. (2018) (146)
- The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL (2009) (139)
- A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis (1997) (136)
- Tizanidine treatment of spasticity caused by multiple sclerosis: Results of a double‐blind, placebo‐controlled trial (1994) (131)
- Natalizumab reduces visual loss in patients with relapsing multiple sclerosis (2007) (127)
- Monoclonal anti-gamma interferon antibodies enhance experimental allergic encephalomyelitis. (1993) (119)
- Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study (2014) (118)
- Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics. (2014) (115)
- GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study (2009) (113)
- Clinical features and diagnosis of multiple sclerosis. (2005) (108)
- Rapid disease course in African Americans with multiple sclerosis (2010) (104)
- Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis (2011) (96)
- Reactivation of JC virus and development of PML in patients with multiple sclerosis (2007) (96)
- Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study. (2014) (94)
- The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL (2009) (94)
- Delayed, relapsing experimental allergic encephalomyelitis in mice. (1981) (93)
- Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis (2004) (91)
- Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. (2006) (86)
- Multiple Sclerosis and Other Inflammatory Demyelinating Diseases of the Central Nervous System (2008) (85)
- Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders (2019) (81)
- Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. (1987) (80)
- History of modern multiple sclerosis therapy (2005) (76)
- Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. (2021) (76)
- The sensitivity of the Mini-Mental State Exam in the white matter dementia of multiple sclerosis. (1992) (75)
- Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. (1996) (74)
- Regional cortical thickness in relapsing remitting multiple sclerosis: A multi-center study☆ (2012) (67)
- Antibodies to GM1 and GD1b in patients with motor neuron disease without plasma cell dyscrasia (1989) (64)
- The genetics of multiple sclerosis. A review. (1999) (63)
- Neuroimmunology: modulation of the hamster immune system by photoperiod. (1987) (59)
- Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis (2010) (53)
- Interferon Beta and Glatiramer Acetate Therapy (2012) (52)
- Editors' welcome and a working definition for a multiple sclerosis cure. (2013) (52)
- Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b (1998) (51)
- Placebo‐controlled clinical trials in multiple sclerosis: Ethical considerations (2001) (50)
- Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a (2009) (50)
- Deep Learning for Predicting Enhancing Lesions in Multiple Sclerosis from Noncontrast MRI. (2019) (49)
- Lower extremity motor evoked potentials in multiple sclerosis. (1991) (46)
- The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability (2017) (46)
- Cerebellar lobule atrophy and disability in progressive MS (2017) (45)
- Characterization of the mitochondrial DNA in patients with multiple sclerosis (1996) (44)
- Brain and lesion segmentation in multiple sclerosis using fully convolutional neural networks: A large-scale study (2020) (44)
- Infusion-related hypersensitivity reactions during natalizumab treatment (2006) (42)
- No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a (2018) (41)
- Interleukin-6 induction in vitro in mouse brain endothelial cells and astrocytes by exposure to mouse hepatitis virus (MHV-4, JHM) (1993) (41)
- Considerations on discontinuing natalizumab for the treatment of multiple sclerosis (2010) (41)
- Hydrocephalus in Kartagener's syndrome. (1986) (40)
- Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial (2020) (40)
- Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use (2013) (39)
- The 2013 clinical course descriptors for multiple sclerosis (2020) (39)
- Palliative care in patients with multiple sclerosis. (2001) (38)
- Disease activity free status in MS. (2012) (38)
- Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis. (2015) (37)
- Association of Deep Gray Matter Damage With Cortical and Spinal Cord Degeneration in Primary Progressive Multiple Sclerosis. (2015) (36)
- Clinical characteristics of progressive relapsing multiple sclerosis (2004) (36)
- Relapses in multiple sclerosis: Relationship to disability. (2016) (36)
- Novel Agents for Relapsing Forms of Multiple Sclerosis. (2016) (35)
- MS COSTAR: A computerized patient record adapted for clinical research purposes (1994) (34)
- Multiple sclerosis: new treatment trials and emerging therapeutic targets (2008) (34)
- Neuroendocrine Regulation of Immune Parameters (1988) (34)
- Retinal degeneration in primary-progressive multiple sclerosis: A role for cortical lesions? (2017) (34)
- X-linked pure familial spastic paraparesis. Characterization of a large kindred with magnetic resonance imaging studies. (1995) (32)
- Dissociable cognitive patterns related to depression and anxiety in multiple sclerosis (2020) (32)
- Trigeminal neuralgia in a patient with multiple sclerosis treated with high cervical spinal cord stimulation. Case report. (1988) (32)
- Atypical Chédiak-Higashi syndrome with attenuated phenotype: three adult siblings homozygous for a novel LYST deletion and with neurodegenerative disease (2013) (31)
- Ethics of placebo-controlled clinical trials in multiple sclerosis (2008) (31)
- The incomplete nature of multiple sclerosis relapse resolution (2007) (30)
- Myokymia and impaired muscular relaxation with continuous motor unit activity. (1979) (29)
- Association of subacute motor neuronopathy with thymoma (1984) (29)
- Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis (2015) (27)
- Word-finding difficulty is a prevalent disease-related deficit in early multiple sclerosis (2019) (27)
- Restoring immune tolerance in neuromyelitis optica (2016) (27)
- Natalizumab reduces relapse clinical severity and improves relapse recovery in MS. (2014) (27)
- Down-regulation of interferon-γ-induced class II expression on human glioma cells by recombinant interferon-β: effects of dosage treatment schedule (1988) (26)
- Distributional Patterns of Multiple Sclerosis Brain Lesions Magnetic Resonance ImagingClinical Correlation (1994) (26)
- A CD4-CDR3 peptide analog inhibits both primary and secondary autoreactive CD4+ T cell responses in experimental allergic encephalomyelitis. (1996) (26)
- Guidelines for clinical trials of new therapeutic agents in multiple sclerosis (1997) (25)
- Acute experimental allergic encephalomyelitis in radiation bone marrow chimeras between high and low susceptible strains of mice (1986) (25)
- Treatment of multiple sclerosis exacerbations. (2011) (24)
- Neurotherapeutics in multiple sclerosis: novel agents and emerging treatment strategies. (2008) (24)
- Quantitative functional MR imaging of the visual cortex at 1.5 T as a function of luminance contrast in healthy volunteers and patients with multiple sclerosis. (2002) (24)
- Synchronization and variability imbalance underlie cognitive impairment in primary-progressive multiple sclerosis (2017) (24)
- Detection of subtle gait disturbance and future fall risk in early multiple sclerosis (2020) (24)
- Neuroendocrine regulation of immune parameters: Photoperiod control of the spleen in Syrian hamsters (1987) (23)
- Regional Gray Matter Atrophy in Relapsing Remitting Multiple Sclerosis: Baseline Analysis of Multi-Center Data (2015) (23)
- Diagnostic Criteria, Classification and Treatment Goals in Multiple Sclerosis: The Chronicles of Time and Space (2016) (23)
- Efficacy and safety of ocrelizumab in relapsing multiple sclerosis: Results of the IFN-β-1a-controlled, double-blind, Phase III OPERA I and II studies (2016) (22)
- A Framework of Care in Multiple Sclerosis, Part 2: Symptomatic Care and Beyond. (2017) (22)
- Delayed, relapsing experimental allergic encephalomyelitis in mice Role of adjuvants and pertussis vaccine (1982) (22)
- Impaired IFN-γ production and proliferation of NK cells in multiple sclerosis. (2011) (22)
- Early complement genes are associated with visual system degeneration in multiple sclerosis. (2019) (22)
- Effects of staphylococcal enterotoxin B on T cell receptor Vβ utilization and clinical manifestations of experimental allergic encephalomyelitis (1993) (22)
- Deep‐Learning‐Based Neural Tissue Segmentation of MRI in Multiple Sclerosis: Effect of Training Set Size (2020) (21)
- Restoring immune tolerance in neuromyelitis optica (2016) (21)
- Interferon-γ-inducible endothelial cell class II major histocompatibility complex expression correlates with strain- and site-specific susceptibility to experimental allergic encephalomyelitis (1993) (21)
- Multiple sclerosis trial designs for the 21st century: Building on recent lessons (2005) (20)
- Meningeal carcinomatosis complicating gynecologic malignancies: a literature review and report of a case. (1983) (20)
- Bacterial neurotoxic metabolites in multiple sclerosis cerebrospinal fluid and plasma. (2021) (20)
- Cerebellar volume as imaging outcome in progressive multiple sclerosis (2017) (20)
- Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: Reporting extended results from phase III clinical trials (1999) (20)
- A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis (2020) (19)
- Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010. (2012) (19)
- Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study (2018) (19)
- Relapsing experimental allergic encephalomyelitis an autoimmune model of multiple sclerosis (2004) (18)
- Characteristics of the T lymphocytes involved in experimental allergic encephalomyelitis (1995) (18)
- Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial (2022) (18)
- How patients with multiple sclerosis acquire disability (2022) (18)
- Intravenous immunoglobulin in relapsing-remitting multiple sclerosis (2008) (18)
- Relapses do not matter in relation to long-term disability: No (they do) (2011) (18)
- GLANCE (2009) (17)
- Open-label, add-on trial of cetirizine for neuromyelitis optica (2018) (17)
- Psychological resilience is linked to motor strength and gait endurance in early multiple sclerosis (2020) (17)
- Screening for Leber's hereditary optic neuropathy associated mitochondrial DNA mutations in patients with prominent optic neuritis (1997) (17)
- Future treatment approaches to multiple sclerosis. (2014) (17)
- Clomiphene as an anticonvulsant drug: A case report. (1982) (16)
- Adoptive transfer of murine relapsing experimental allergic encephalomyelitis (1985) (16)
- Phase-Sensitive Inversion-Recovery MRI Improves Longitudinal Cortical Lesion Detection in Progressive MS (2016) (16)
- Immunotherapy of multiple sclerosis--current practice and future directions. (2002) (15)
- Magnetic Resonance Imaging of Meningoradiculomyelitis in Early Disseminated Lyme Disease (2003) (15)
- Ocrelizumab No Evidence of Disease Activity (NEDA) Status at 96 Weeks in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III Double-Blind, Double-Dummy, Interferon beta-1a-Controlled OPERA I and OPERA II Studies (PL02.004) (2016) (15)
- Natalizumab significantly increases the cumulative probability of sustained improvement in physical disability (2008) (14)
- Clinical results from AFFIRM: A randomized, double-blind, placebo-controlled, multicenter trial to determine the efficacy and safety of natalizumab in patients with relapsing multiple sclerosis (MS) (2005) (14)
- Relapsing experimental allergic encephalomyelitis in radiation bone marrow chimeras between high and low susceptible strains of mice. (1986) (14)
- Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years. (2017) (14)
- The Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and The MS Council for Clinical Practice Guidelines (2002) (14)
- Effect of in‐painting on cortical thickness measurements in multiple sclerosis: A large cohort study (2015) (13)
- Distribution of the Blood‐Brain Barrier in Heterotopic Brain Transplants and its Relationship to the Lesions of EAE (1992) (13)
- Differentiating multiple sclerosis from other causes of demyelination using diffusion weighted imaging of the corpus callosum (2009) (13)
- Emergency Medical Care of Multiple Sclerosis Patients: Primary Data from the Mount Sinai Resource Utilization in Multiple Sclerosis Project (2014) (13)
- Modulation of T cell–endothelial adhesion by astrocyte conditioned medium (1997) (13)
- Mouse hepatitis virus (MHV-4, JHM) blocks γ-interferon-induced major histocompatibility complex class II antigen expression on murine cerebral endothelial cells (1991) (13)
- Tissue segmentation by high resolution MRI: improved accuracy and stability (1994) (12)
- The 'Field Hypothesis': rebound activity after stopping disease-modifying therapies. (2017) (12)
- Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials (2020) (12)
- Susceptibility to experimental allergic encephalomyelitis in animal models of autoimmunity. (1992) (12)
- The relationship between cortical lesions and periventricular NAWM abnormalities suggests a shared mechanism of injury in primary-progressive MS (2017) (12)
- Brain microstructural injury occurs in patients with RRMS despite ‘no evidence of disease activity’ (2018) (12)
- Brain and cervical spinal cord atrophy in primary progressive multiple sclerosis: results from a placebo-controlled phase III trial (INFORMS) (2015) (12)
- Role of myelin antigens in murine relapsing experimental allergic encephalomyelitis. (1984) (11)
- A clinically feasible 7-Tesla protocol for the identification of cortical lesions in Multiple Sclerosis (2020) (11)
- Impairment of central and peripheral myelin in mitochondrial diseases (1997) (11)
- When marketing and science intersect: do patients with MS benefit? (2002) (10)
- Interferon beta-1B induced ulcerative skin lesions in MS (1994) (10)
- Axonal water fraction as marker of white matter injury in primary‐progressive multiple sclerosis: a longitudinal study (2019) (10)
- Regulation of the expression of intercellular adhesion molecule-1 (ICAM-1) and the putative adhesion molecule Basigin on murine cerebral endothelial cells by MHV-4 (JHM). (1993) (10)
- Immunopathogenic mechanisms in experimental allergic encephalomyelitis. (1993) (10)
- The 2013 Clinical Course Descriptors for Multiple Sclerosis (2020) (10)
- Depression and cognitive function in early multiple sclerosis: Multitasking is more sensitive than traditional assessments (2020) (9)
- Study Design and Baseline Characteristics of the INFORMS Study: Fingolimod in Patients with Primary Progressive Multiple Sclerosis (P07.116) (2013) (9)
- Relationship of urinary myelin basic protein-like material with cranial magnetic resonance imaging in advanced multiple sclerosis. (2001) (9)
- Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (2021) (9)
- Heterotopic brain transplants in the study of experimental allergic encephalomyelitis (1987) (9)
- Combination therapy in multiple sclerosis (2005) (9)
- Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: The difficulty of predicting relapses. (2021) (9)
- Relationship between timed 25-foot walk and diffusion tensor imaging in multiple sclerosis (2016) (9)
- Clinically isolated syndrome and multiple sclerosis: Rethinking the arsenal (2009) (9)
- Use of interferon-beta in the treatment of multiple sclerosis. (2006) (9)
- Organ specific endothelial cell heterogeneity influences differential replication and cytopathogenicity of MHV-3 and MHV-4. Implications in viral tropism. (1995) (9)
- Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis (2021) (8)
- The CombiRx Trial: A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Participants with Relapsing-Remitting Multiple Sclerosis – Clinical Outcomes (PL02.003) (2012) (8)
- Primary Neurolymphomatosis Presenting With Polyradiculoneuropathy Affecting One Lower Limb (2015) (8)
- CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis (2021) (8)
- Spectrum and classification of inflammatory demyelinating diseases of the central nervous system (2001) (8)
- Central nervous system and blood lymphocytes in experimental allergic encephalomyelitis. (1983) (8)
- Multimodal MRI Segmentation of Brain Tissue and T2-Hyperintense White Matter Lesions in Multiple Sclerosis using Deep Convolutional Neural Networks and a Large Multi-center Image Database (2018) (8)
- Efficacy of Ocrelizumab in Patients with Relapsing Multiple Sclerosis: Pooled Analysis of Two Identical Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled Studies (S49.003) (2016) (8)
- The MS Co-O perative Research (MS-CORE) group: an alternate approach to fostering multicenter studies (2004) (7)
- Regulation of MHC class I and II antigens on cerebral endothelial cells and astrocytes following MHV-4 infection. (1990) (7)
- Down-regulation of interferon-gamma-induced class II expression on human glioma cells by recombinant interferon-beta: effects of dosage treatment schedule. (1988) (7)
- The diagnosis of multiple sclerosis (2002) (7)
- T cell receptor Vβ gene utilization in myelin basic protein specific clones from CXJ1 recombinant inbred mice (1993) (7)
- Looking into cognitive impairment in primary‐progressive multiple sclerosis (2018) (7)
- Recruitment of participants to a multiple sclerosis trial: The CombiRx experience (2014) (7)
- Multiple Sclerosis Classification and Overview (2004) (7)
- Syringoencephalomyelia (Syringocephalus) (1981) (7)
- Dietary factors and MRI metrics in early Multiple Sclerosis. (2021) (7)
- Myelin basic protein‐specific protein methylase I activity in shiverer mutant mouse brain (1986) (7)
- Impact of Ocrelizumab on Cognition in Patients at Increased Risk of Progressive Disease (P1.420) (2018) (7)
- Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis (2022) (7)
- Preferential but not exclusive T cell receptor V beta chain utilization of myelin basic protein and peptide-specific T cell clones in mice. (1994) (7)
- Teriflunomide Reduces Relapse-Related Sequelae, Hospitalizations and Corticosteroid Use: A Post-Hoc Analysis of the Phase 3 TOWER Study (P07.109) (2013) (7)
- Erratum: The efficacy of natalizumab in patients with relapsing multiple sclerosis: Subgroup analyses of AFFIRM and SENTINEL (Journal of Neurology (2009) 256 (405-415) DOI: 10.1007/s00415-009-0093-1) (2009) (7)
- Combination therapy for treatment of multiple sclerosis (1998) (7)
- Long-Term Safety of Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Results from Phase 3 FREEDOMS II Extension Study (P01.165) (2013) (6)
- Clinical course in multiple sclerosis patients presenting with a history of progressive disease. (2014) (6)
- Optic neuropathy in late-onset neurodegenerative Chédiak–Higashi syndrome (2015) (6)
- Immunomodulation of relapsing experimental allergic encephalomyelitis (1984) (6)
- Correlation between structural brain lesions and emotional and cognitive function in patients with multiple sclerosis: an MRI study (1992) (6)
- “Location, location, location” (2018) (6)
- Lymphocyte counts and infection rates (2019) (6)
- Baseline Demographics and Disease Characteristics from OPERA I and II, Two Phase III Trials Evaluating Ocrelizumab in Patients with Relapsing Multiple Sclerosis (P7.201) (2015) (5)
- Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum (2021) (5)
- Separation and properties of lymphocytes obtained from the central nervous system. (1980) (5)
- MS COSTAR: A Computerized Record for Use in Clinical Research in Multiple Sclerosis: (1993) (5)
- Chapter 2 Clinical Features and Subtypes of Multiple Sclerosis (2003) (5)
- Interferon-gamma-inducible endothelial cell class II major histocompatibility complex expression correlates with strain- and site-specific susceptibility to experimental allergic encephalomyelitis. (1993) (5)
- Commentary II (2007) (5)
- Experimental Models of Autoimmune Demyelination (2001) (5)
- CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances. (2016) (5)
- Effect of Teriflunomide on Relapses with Sequelae and Relapse Leading to Hospitalization in a Population with Relapsing Forms of Multiple Sclerosis: Results from the TEMSO Study (S30.003) (2012) (5)
- Intracerebral uric acid as a marker of brain infection with MHV-4 (1994) (5)
- Sleep disturbance and memory dysfunction in early multiple sclerosis (2021) (5)
- Down‐Regulation of Gamma‐Interferon‐Induced Class II Expression of Human Glioma Cells by Recombinant Beta‐interferon (1988) (5)
- Treatment of multiple sclerosis with interferon beta-1b (1997) (5)
- Results of the Phase 3 SPI2 Study of MD1003 (high dose Pharmaceutical grade Biotin) in Progressive MS (680) (2020) (5)
- Relapse Is Associated with Residual Deficits in Relapsing-Remitting Multiple Sclerosis: Analysis of FREEDOMS Data (P07.118) (2013) (4)
- Hippocampal volume is more related to patient-reported memory than objective memory performance in early multiple sclerosis (2020) (4)
- Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary note (2017) (4)
- The efficacy of natalizumab on magnetic resonance imaging (MRI) measures in patients with relapsing multiple sclerosis (MS): Results from the AFFIRM trial (2005) (4)
- Multiple Sclerosis and Other Inflammatory Diseases (2016) (4)
- A Framework of Care in Multiple Sclerosis, Part 1 (2016) (4)
- OPL100 The effects of natalizumab on disability progression as measured by the Multiple Sclerosis Functional Composite (MSFC) and visual function in patients with relapsing MS (2005) (4)
- The effects of natalizumab on brain atrophy and cognitive function: results from the AFFIRM study (2006) (4)
- Genetic regulation of susceptibility and severity of demyelination (1987) (4)
- Influenza immunization in multiple sclerosis (1997) (4)
- Outcomes in Patients with Progressive MS: Analysis of Teriflunomide Long-Term Extension Data (P3.038) (2016) (4)
- EDSS Changes in CombiRx: Blinded, 7-Year Extension Results for Progression and Improvement (P04.121) (2013) (4)
- Fingolimod Reduces Annualized Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis: FREEDOMS II Study Subgroup Analysis (P07.102) (2013) (4)
- Relapse Activity in the CombiRx Trial: Blinded, 7-Year Extension Results (S01.002) (2013) (3)
- Brain Transplantation in Genetic Analysis of Experimental Allergic Encephalomyelitis a (1988) (3)
- Diagnosis and Differential Diagnosis of Multiple Sclerosis (2013) (3)
- 061 Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis (RMS) (ENCORE) (2018) (3)
- Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a (2020) (3)
- The Association Between Confirmed Disability Progression and Patient-Reported Fatigue in PPMS Patients in the ORATORIO study (S33.006) (2017) (3)
- Genetic Regulation of Susceptibility and Severity of Demyelination a (1988) (3)
- Efficacy Outcome Measures of Oral Ponesimod Compared to Teriflunomide in Patients with Relapsing Multiple Sclerosis: Results of the Randomized, Active-Controlled, Double-Blind, Parallel-Group Phase 3 OPTIMUM Study (3972) (2020) (3)
- Effect of Ocrelizumab on Disability Progression in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled OPERA I and OPERA II Studies (S49.008) (2016) (3)
- Impact of Relapses with Sequelae on Disability, Health-Related Quality of Life, and Fatigue in a Population with Relapsing Forms of Multiple Sclerosis Using Data from TEMSO, a Pivotal Phase III Teriflunomide Trial (P07.082) (2012) (3)
- The cellular response of JC virus T-antigen-induced brain tumor implants to a Murine intra-ocular model (2000) (3)
- Objective and subjective measures of dalfampridine efficacy in clinical practice (2018) (3)
- A composite measure to explore visual disability in primary progressive multiple sclerosis (2017) (3)
- Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course (2016) (3)
- Effect of Ocrelizumab on MRI Inflammatory and Neurodegenerative Markers of Disease in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled OPERA I and OPERA II Studies (S49.002) (2016) (3)
- Natalizumab increases the proportion of patients free of clinical or MRI disease activity in relapsing multiple sclerosis (2008) (2)
- Impaired IFN- g production and proliferation of NK cells in Multiple Sclerosis (2011) (2)
- Sustained Improvement in Physical Disability with Natalizumab in Patients with Relapsing Multiple Sclerosis (2009) (2)
- Editors' Welcome. (2017) (2)
- Natalizumab-Treated Patients with Multiple Sclerosis Have Low Rates of Brain Volume Decrease and Low MRI Disease Activity in the Long-term STRATA Study (P7.260) (2015) (2)
- MS as a gateway disease (2013) (2)
- Urinary tract infection frequency in MS exacerbations (1994) (2)
- Multiple Sclerosis is a multifaceted disease. (2014) (2)
- Evaluating multiple sclerosis (2004) (2)
- Multiple Sclerosis: An Overview (2017) (2)
- MRI Outcomes in CombiRx: Blinded, 7-Year Extension Results (S01.003) (2013) (2)
- Effects of natalizumab treatment on freedom from disease activity by baseline characteristics in AFFIRM (2013) (2)
- Disability outcomes in early-stage African American and White people with multiple sclerosis. (2022) (2)
- Pandemic forward: Lessons learned and expert perspectives on multiple sclerosis care in the COVID-19 era (2020) (2)
- Cytokine induction in vitro in mouse brain endothelial cells and astrocytes by exposure to mouse hepatitis virus (MHV-4, JHM). (1993) (2)
- William Austin Sibley, MD (1925–2015) (2016) (2)
- PO129 Neda analysis by epoch in the opera studies of ocrelizumab (2017) (2)
- Autoimmune inflammation of astrocyte transplants (1992) (2)
- New criteria for the diagnosis of multiple sclerosis (2005) (2)
- Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients with Relapsing Multiple Sclerosis in the OPERA I and OPERA II Trials (2018) (2)
- Analysis of cerebral microvessel endothelial cell junctional permeability in experimental allergic encephalomyelitis susceptible and resistant mice (1991) (2)
- Interferon β in Multiple Sclerosis (2016) (1)
- Generation of an anti-mouse brain endothelial cell monoclonal antibody that recognizes 84-110 kDa and 36 kDa determinants that are upregulated by cytokines. (1993) (1)
- Editors' Welcome. (2017) (1)
- Brain Volume as a Predictor of Disability in Primary Progressive Multiple Sclerosis: Evidence from the INFORMS Trial (S51.007) (2016) (1)
- Effect of Fingolimod in Patients with No Disability as Measured by EDSS at Baseline: Post-Hoc Analyses of FREEDOMS I and II (P07.124) (2013) (1)
- A Genetic Model To Predict Response to Glatiramer Acetate Developed from a Genome Wide Association Study (GWAS) (IN3-2.003) (2012) (1)
- Pain in patients with multiple sclerosis: Effects of natalizumab (2008) (1)
- Multiple Sclerosis Patients with No Evidence of Disease Activity in the 2-Year AFFIRM Study Have Better Outcomes with Long-term Natalizumab Treatment than Patients Who Had Evidence of Disease Activity in AFFIRM (P7.221) (2015) (1)
- Brain Transplantation in the Study of Host Regulation of Susceptibility to Experimental Allergic Encephalomyelitis a (1987) (1)
- DIFFERENTIAL ADHESION OF MBP SPECIFIC CD4+ T CELL HYBRIDOMA CLONES TO CEREBROMICROVASCULAR AND PERIPHERAL ENDOTHELIUM (1994) (1)
- Incorporating personalized patient management strategies into the treatment of Multiple Sclerosis (2016) (1)
- Natalizumab increases the proportion of disease-free patients in relapsing multiple sclerosis (2008) (1)
- Electron microscopical diagnosis of lipidosis with the use of rectal biopsy. (1974) (1)
- Dalfampridine Real World Utilization and Efficacy Assessment (P7.244) (2014) (1)
- Survival and immunogenicity of neural grafts (1991) (1)
- MHC antigen modulation on mouse brain endothelial cells, astrocytes and macrophages induced by MHV-4 infection (1987) (1)
- S853 Long-term Safety of Ozanimod in Patients with Moderately to Severely Active Ulcerative Colitis (UC) and Relapsing Multiple Sclerosis (RMS) Studies (2021) (1)
- Complete clinical and magnetic resonance imaging response with natalizumab in multiple sclerosis (2008) (1)
- MS COSTAR: A Computerized Record for Use in Clinical Research in Multiple Sclerosis (1993) (1)
- Confirming a Historical Diagnosis of Multiple Sclerosis: Challenges and Recommendations. (2022) (1)
- The incidence and clinical significance of antibodies to natalizumab over 2 years of treatment in patients with multiple sclerosis (2006) (1)
- Cerebellar pathology and disability worsening in relapsing‐remitting multiple sclerosis: A retrospective analysis from the CombiRx trial (2021) (1)
- Biomarkers and Relapse in CombiRx (P5.221) (2015) (1)
- Erratum: Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics (Brain (2014) 137 (2271-2286) DOI: 10.1093/brain/awu139) (2015) (1)
- The effects of natalizumab on disability progression in the AFFIRM study: correlation between changes in Multiple Sclerosis Functional Composite and Expanded Disability Status Scale scores (2005) (1)
- Natalizumab improves health-related quality of life in patients with relapsing multiple sclerosis (2006) (1)
- Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis (2022) (1)
- Immune Effects of Intracerebral Infection with Mouse Hepatitis Virusa (1988) (1)
- The Effect of Body Mass Index on Brain Volume and Cognitive Function in Relapsing–Remitting Multiple sclerosis: A CombiRx Secondary Analysis (2021) (1)
- Commentary I (2007) (1)
- Differences in class II MHC expression on cerebral microvessel endothelial cells in experimental allergic encephalomyelitis susceptible and resistant mice (1991) (1)
- A Genetic Model Predicts the Response to Glatiramer Acetate in Two Different Cohorts (P05.129) (2012) (1)
- Intracerebral beta interferon in brain tumor therapy: Monitoring cerebral function with compressed spectral analysis (1987) (1)
- β-interferon induced ulcerative skin lesions (1995) (1)
- Depression and MRI Metrics in the CombiRx Trial (P5.198) (2015) (0)
- Editors' welcome. (2015) (0)
- Responsiveness and predictive values in PPMS (2008) (0)
- Quantification of white matter tract integrity in primary-progressive multiple sclerosis: a longitudinal study (2018) (0)
- Editors' Welcome. (2015) (0)
- Breaking news on results of recently completed trials (2016) (0)
- β-intarferon (Betaseron) treatment prevents worsening of VEP in MS (1995) (0)
- Editors' Welcome. (2017) (0)
- Lymphocyte Dynamics During and After Fingolimod Therapy: Long-Term Data from the INFORMS Trial (P5.294) (2016) (0)
- Diffusional Kurtosis MRI Correlates Of Cognitive Functions In Primary-Progressive MS (P6.122) (2014) (0)
- GENETIC REGULATION OF EAE SUSCEPTIBILITY: VARIATIONS IN THE PATTERN OF LYMPHOCYTE DISTRIBUTION IN THE CNS (1990) (0)
- Longitudinal Clinical and MRI Outcomes in Relapsing Multiple Sclerosis (RMS) Patients After Short-term Ponesimod Treatment Interruption and Re-initiation (P6-3.007) (2023) (0)
- Editors' Welcome. (2017) (0)
- Development of Therapeutic Area-Specific Data Standards for Brain Diseases (S9.007) (2015) (0)
- Association of Deep GrayMatter Damage With Cortical and Spinal Cord Degeneration in Primary ProgressiveMultiple Sclerosis (2015) (0)
- Treatment of multiple sclerosis with interferon beta-1b - Reply (1997) (0)
- The effects of natalizumab on disability and health-related quality of life in patients with relapsing MS (2006) (0)
- Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple Sclerosis (2022) (0)
- Editors' Welcome. (2018) (0)
- INFLUENZA IMMUNIZATION IN MULTIPLE SCLEROSIS. AUTHORS' REPLY (1997) (0)
- The effect of natalizumab on brain atrophy and its relationship with cognitive function in multiple sclerosis (2006) (0)
- Sa.32. The Immunogenicity of Natalizumab in Patients with Multiple Sclerosis (2006) (0)
- Editors' welcome. (2012) (0)
- The incidence and clinical significance of antibodies to natalizumab: 2-year results from the AFFIRM study (2005) (0)
- Editors' Welcome. (2016) (0)
- TREATMENT OF MULTIPLE SCLEROSIS WITH INTERFERON BETA-1B. AUTHORS' REPLY (1997) (0)
- Editors׳ welcome. (2014) (0)
- Contribution of Cortical Lesions to Cognitive Dysfunction in the PPMS Population: Comparison of Double Inversion Recovery (DIR) and Phase Sensitive Inversion Recovery (PSIR) Sequences Using a 3 Tesla MRI. (P6.144) (2015) (0)
- Cortical lesion load correlates with periventricular NAWM damage severity in PPMS (2016) (0)
- Editors׳ welcome. (2014) (0)
- Natalizumab reduces loss of visual function in patients with relapsing multiple sclerosis (2006) (0)
- Editors׳ welcome. (2015) (0)
- Editors' Welcome. (2015) (0)
- TREATMENTS FOR MULTIPLE SCLEROSIS (2004) (0)
- Controversies in Multiple Sclerosis Therapy (2014) (0)
- Baseline cerebellar volume as short-term predictor of clinical disability in Multiple Sclerosis: MRI Findings from the CombiRx trial (S6.005) (2018) (0)
- Editors' welcome. (2014) (0)
- Editor's Welcome. (2012) (0)
- Magnetic resonance imaging results from AFFIRM: a randomised controlled trial of natalizumab in patients with relapsing multiple sclerosis (2005) (0)
- Sporadic Creutzfeldt-Jakob Disease With Unilateral Symptoms in the Setting of Metastatic Renal Cell Carcinoma (2017) (0)
- Myokymia andimpaired muscular relaxation with continuous motorunit activity (1979) (0)
- SYRINGOCEPHALUS – EXTENSION OF A SYRINX INTO THE CENTRUM SEMI-OVALE (1978) (0)
- Betaseron treatment worsening of VEP in MS (1995) (0)
- PO128 Infusion-related reactions with ocrelizumab in rms and ppms (2017) (0)
- Long-term Outcomes in Patients with Progressive MS with Relapses: Analysis of TEMSO and TOWER Extension Data (S33.008) (2017) (0)
- Reply from the Authors to Drs. Milanese, Savettieri, and Terizan (1996) (0)
- ReducedS-adenosylmethionine: Protein-lysineN-methyltransferase activity (protein methylase III) in shiverer mutant mouse brain (1987) (0)
- Author response. (2015) (0)
- Editors' welcome. (2015) (0)
- Relationship between RNFL thickness and Brain Cortical Lesions in Primary-Progressive MS (P6.109) (2015) (0)
- Editors' Welcome. (2016) (0)
- Gray and white matter spinal cord correlates of clinical disability in progressive MS patients (2017) (0)
- Optimizing Outcomes in Multiple Sclerosis – A Consensus Initiative (2009) (0)
- Gray matter atrophy and clinical evolution in progressive MS (P6.162) (2015) (0)
- Regional Gray Matter Atrophy in Multiple Sclerosis using Tensor Based Morphometry : A Multi-Center Study (2012) (0)
- Monthly screening for neuropsychological impairment in multiple sclerosis (2007) (0)
- A composite MRI and OCT based measure to explore the visual pathways in primary-progressive Multiple Sclerosis (P6.405) (2017) (0)
- Management of Multiple Sclerosis, Part 1 of 2: Differential DiagnosisA Consensus Approach (2009) (0)
- OPL114 The effects of baseline disease activity on magnetic resonance imaging (MRI) outcomes in the AFFIRM study (2005) (0)
- Long-Term Follow-Up of Laquinimod 0.6 mg in Patients with Relapsing-Remitting Multiple Sclerosis 2 (P3.087) (2016) (0)
- Functional System Changes Associated with Relapse: The CombiRx Experience (P3.285) (2015) (0)
- Editors' Welcome. (2017) (0)
- IFNB IN MS. AUTHORS' REPLY (1996) (0)
- Immunomodulatory networks in multiple sclerosis (2020) (0)
- The impact of relapse definition and measures of durability on MS clinical trial outcomes (2023) (0)
- The incidence and specificity of allergies in patients with multiple sclerosis (1991) (0)
- OCRELIZUMAB VS INTERFERON β-1A IN RELAPSING MS: TWO STUDIES (2016) (0)
- Editors' welcome. (2012) (0)
- Editors' Welcome. (2016) (0)
- Organ specific endothelial cell heterogeneity may regulate CNS tropism of different strains of mouse hepatitis virus (MHV) (1994) (0)
- Analysis of lymphocyte counts and infection rates with fingolimod in patients with primary progressive multiple sclerosis over the INFORMS trial (P1.387) (2018) (0)
- Unicuique suum: Investigating cerebellar lobules contribution to clinical disability in progressive multiple sclerosis (2017) (0)
- Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial (2023) (0)
- Emerging Therapies in Multiple Sclerosis CME (2010) (0)
- MBP promoter upregulation by activated T cell products (1994) (0)
- Brain transplantation in genetic analysis of EAE (1987) (0)
- The presence of antibodies reacting with GM1 in motor neuron disease patients without plasma cell dyscrasia (1987) (0)
- Trial design and baseline data of the INFORMS (fingolimod in patients with primary progressive multiple sclerosis) study (2012) (0)
- Early first‐line treatment response and subsequent disability worsening in relapsing–remitting multiple sclerosis (2021) (0)
- Interferon Beta and Glatiramer Acetate Therapy (2012) (0)
- Relationship Between Timed 25-Foot Walk Impairment and Diffusion Tensor Imaging Markers in Multiple Sclerosis (P4.017) (2015) (0)
- 3527 Intensity normalization for improved MR images analysis (2013) (0)
- Editors' Welcome. (2016) (0)
- Predicting Confirmed Disability Progression In MS: Importance Of Early On-Treatment MRI Changes On Modeling The CombiRx Trial Database (P3.157) (2014) (0)
- Intracerebral Beta‐Interferon in Brain Tumor Therapy Monitoring Cerebral Function with Compressed Spectral Analysis a (1988) (0)
- The relationship between disease severity and health-related quality of life in patients with relapsing multiple sclerosis (2006) (0)
- Promoting regeneration and repair in Multiple Sclerosis. (2013) (0)
- Abstracts & Insights on Biomarkers From the 2011 European Meeting in Multiple Sclerosis CME (2011) (0)
- The effects of natalizumab monotherapy on multiple measures of disability progression in MS patients (2006) (0)
- Mouse hepatitis virus (MHV-4, JHM) blocks γ-interferon-induced MHC class II antigen expression on murine cerebral endothelial cells (1991) (0)
- An Open Label Add-On Trial of Cetirizine for Neuromyelitis Optica (P4.003) (2015) (0)
- Relationship between imaging and blood-based transcription profiles in primary-progressive multiple sclerosis (2014) (0)
- Predictors of Disease Activity and Worsening in Relapsing-Remitting Multiple Sclerosis (2022) (0)
- Editors' Welcome. (2015) (0)
- High Circulating Levels of Vitamin D Associated with Reduced MS Risk (2007) (0)
- Editors' Welcome. (2016) (0)
- Segmentation analysis in the volumetric measurement and tissue characterization of MS lesions over time (1995) (0)
- Blood-based Transcriptomic and Clinical/MRI Measures Correlate in Primary-Progressive MS (P6.122) (2015) (0)
- Impact of sustained disability progression and relapses on visual outcomes in the AFFIRM trial (2007) (0)
- Editors' welcome. (2014) (0)
- Real-world studies provide reliable comparisons of disease modifying therapies in MS – Commentary (2020) (0)
- Multitasking is the Cognitive Ability Most Linked to Depression in Multiple Sclerosis (P5.028) (2018) (0)
- Down regulation of IFN-gamma induced class II expression on human glioma cells by recombinant beta interferon (1987) (0)
- The Timed 25-foot Walk Test as an Alternative to EDSS Score for Evaluating ‘No Evidence of Disease of Activity’ (NEDA-4) Status in Patients with RRMS (P2.143) (2016) (0)
- Immune effect of intracerebral infection with mouse hepatitis virus (1987) (0)
- Mouse brain endothelial cells and astrocytes derived from susceptible and resistant strains of mice synthesize interleukin-6 in response to MHV-4 infection in vitro (1991) (0)
- Quantitative functional MRI of the visual cortex as a function of luminance contrast at 1.5 T (1999) (0)
- Editors' Welcome. (2017) (0)
- Relationship between Spinal Cord Atrophy and Brain Cortical Lesions in Primary-Progressive MS (P6.137) (2014) (0)
- Contents Vol. 51,1988 (1988) (0)
- Multiple sclerosis as a model neurologic disease. (2011) (0)
- The immunogenicity of natalizumab in patients with multiple sclerosis: Results from the AFFIRM study (2007) (0)
- Measuring Enduring Worsening Of Multiple Sclerosis In The CombiRx Study (S34.007) (2014) (0)
- Effects of Live-Online Education on Multiple Sclerosis Disease Management: Changes in Patient Experience, Clinical Practice, Provider Knowledge and Competence (P2.422) (2018) (0)
- Spinal Cord Atrophy and Clinical Disability in Primary-Progressive MS: A 1-Year Follow-Up Study (P6.167) (2015) (0)
- CSF from MS Patients Induces Mitochondrial Dysfunction in Unmyelinated Neuronal Cultures (P05.179) (2013) (0)
- Editors' Welcome. (2016) (0)
- Longitudinal Assessment of Multiple Sclerosis Patients and Reimbursement Issues (2005) (0)
- Social/emotional distress as reported by significant others (but not self-report) is correlated with lesion burden in MS (1996) (0)
- Disability Progression in Multiple Sclerosis Patients Treated with Natalizumab in the Long-term STRATA Study (P3.163) (2014) (0)
- Personalizing treatment effect based on patient's baseline profile: a statistical modelling approach applied to randomized clinical trial and observational study data (2019) (0)
- Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy (2022) (0)
- Improved Clinical Detection of Cerebellar Lesions in Multiple Sclerosis Patients (P4.376) (2018) (0)
- MBP specific CD4+ T-cell hybridoma clones demonstrate altered adhesion to cerebromicrovascular endothelial cells when compared to peripheral endothelium (1994) (0)
- Long-term Safety of Ozanimod in Relapsing Multiple Sclerosis and Moderately to Severely Active Ulcerative Colitis (P7-3.007) (2023) (0)
- Editors' welcome. (2017) (0)
- Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy (2022) (0)
- Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials (2023) (0)
This paper list is powered by the following services:
Other Resources About Fred D. Lublin
What Schools Are Affiliated With Fred D. Lublin?
Fred D. Lublin is affiliated with the following schools:
